
Kathleen Doss, MD
Infectious Diseases Fellow, PGY 6
University of Washington, Seattle, WA
kmd8p@uw.edu



- > years s/p for
- > Notices worsening facial edema and diagnosed with IJ DVT and started on Xarelto
- > Progressive facial swelling over the next few months with new skin changes:
  - Spiky bumps and new hair loss of eyelashes, eyebrows and beard
  - Lesions are not painful
- > No fevers, chills, diarrhea, nausea/vomiting etc.



## **Transplant History:**

- CMV D+/R-, EBV D+/R+
- No episodes of rejection
- Post operative course c/b prolonged rhinovirus, VAP, hyperammonemia

## **Social History/Relevant Exposures**

- Lives in
- Worked

now

- No illicit drug use
- No pets
- Outdoor enthusiast

### Immunosuppression:

Tacrolimus, MPA, Prednisone

#### **Antimicrobial prophylaxis:**

TMP/SMX, Azithromycin

## **Vitals:**

Afebrile.

## **Examination:**

General: Comfortable, in no acute

distress.

HEENT: No sinus tenderness, see

skin exam. EOMI. Anicteric

Skin: Innumerable non tender

skin-colored papules on the nose


forehead cheeks ears, many with


a central filiform spike. No

eyebrow hair or eyelashes. Beard

is patchy.


Neuro: Non focal







## Labs:



ANC: 4830

ALC: 520

Tacrolimus 6.8 ng/ml

143	109	42
4.6	24	1.94

AST: 21 U/L

ALT: 17 U/L

Alk Phos: 52 U/L


Tbili: 0.5 mg/dl

## **Poll Question 1:**

What is the most likely etiology of this patient's rash?


- > A. Fungal
- > B. Viral
- > C. Parasitic
- > D. Bacterial
- > E. Noninfectious

## Histopathology



H&E stain, 10x magnification

## Histopathology



H&E stain, 40x magnification


Photo Credit: Mugahed Hamza, MBBS

## **Poll Question 1:**


What is the most likely etiology of this patient's rash?

- > A. Fungal
- > B. Viral
- > C. Parasitic
- > D. Bacterial
- > E. Noninfectious

Nuclear positivity of inner root sheath cells



SV40 Immunostain, original magnification x 20



EM: "bumpy" appearance of viral inclusions

Image Credit: Left: PMID 33354613; Right: PMID: 32475005

## **Poll Question 2:**

What is the most likely virus causing this patient's infection?

- > A. BK Polyomavirus (BKPyV)
- > B. JC Polyomavirus (JCPyV)
- > C. Merkel Cell Polyomavirus (MCPyV)
- > D. Trichodysplasia spinulosa-associated polyomavirus (TSPyV)
- > E. Molluscum Contagiosum
- > F. HIV

## Trichodysplasia Spinulosa



## Trichodysplasia spinulosa

## Overview and history

- > First described in 1995
  - "Disseminated follicular spiny hyperkeratosis"
  - associated with cyclosporine
- > Formally named "Trichodysplasia spinulosa" in 1999 after discovery of viral etiology/associated with cyclosporine in general
- > 2010 TSPyV as causative virus, renamed "Trichodysplasia spinulosa associated polyomavirus



## **Polyomaviruses**

- Family: Polyomaviridae
- Small (40-50nm in diameter)
- Icosahedral, Non-enveloped, DNA viruses
- Hosts: Mammals and birds
- Infection is common, disease is rare
- 15 currently known human polyomaviruses (HPyV)
  - BK Virus
  - \_\_ JC Virus
  - Merkel Cell virus
  - \_ Trichodysplasia spinulosa-associated polyomavirus (TSPyV)

PMID: 34662051
 PMID: 35482045



## Trichodysplasia spinulosa: Epidemiology

- Viral infection is common, clinical disease is rare
  - Seroprevalence of TSPyV between 63%—80% of healthy and immunocompetent adult patients<sup>1-3</sup>
  - Approaches 90% in kidney transplant recipients<sup>4</sup>
- Transmission likely early in childhood between siblings and mother/child
  - Seroprevalence is high from birth until 2 months, subsequently increases from age 3 to age 11 -> adult levels<sup>1,3</sup>
- Geographic distribution unknown
- No Gender predilection

## Trichodysplasia spinulosa: Epidemiology


- > Disease is rare
- > ~40 cases in SOT population<sup>1</sup> (Jose 2020)
- > ~60 cases total<sup>2</sup> (Curman 2021)
- > Risk Factors For Disease<sup>3</sup>
  - Solid organ transplantation
  - HIV
  - Immunosuppressive medications
  - Hematolymphoid malignancy

1.PMID: 32475005 2. PMID: 33559344 3.PMID: 34662051

## Trichodysplasia spinulosa: Pathophysiology

- Virus appears to target keratinocyte inner root sheath epithelium
- Dermal papillae absent in infected follicles which leads to (temporary) alopecia
- > Proposed mechanism of disease
  - Primary exposure
  - Re exposure
  - Reactivation of latent virus
    - > Latent site of reactivation unknown (possibly lymphoid tissue)

## **SKIN ANATOMY**




alamy tmage 10: 286795N www.alamy.com

## Trichodysplasia spinulosa: Clinical Presentation


- Fleshy papules and spicules involving the face
- Rare involvement of trunk and extremities
- Non-scaring alopecia of eyebrows
- Painless
- Occasionally associated with pruritis
- Psychological distress

PMID: 33559344 PMID: 32475005



## Trichodysplasia spinulosa: Diagnosis

- > Gold Standard = PCR of TSPyV in affected tissue (with typical histology + clinical presentation)
  - Viral load PCR  $10^4$  (10<sup>4</sup>–10<sup>7</sup> genome copies per cell)<sup>1</sup>
- > Histopathology



Hematoxylin-eosin, original magnification ×40 and x100<sup>2</sup>

1.PMID: 23593936

2. PMID: 22351786 (Photo Credit)

## Trichodysplasia spinulosa: Diagnosis

- > Transmission Electron Microscopy = intranuclear clusters of icosahedral viral inclusions with a "bumpy" appearance
- > Serology not useful




Photo Credit:

PMID: 32475005

## **Poll Question 3**

What is the most effective treatment?

- > A. Valganciclovir
- > B. Acyclovir
- > C. Fluconazole
- > D. Cidofovir
- > E. Other

## Trichodysplasia spinulosa: Treatment

- > Goal of treatment is to <u>reduce viral load by anti-viral effect or by reduction of</u> immunosuppression
- > Data limited to case report, case series
- > "First line" treatment with <u>reduction of immunosuppression, 3% topical cidofovir</u> (in vitro data), <u>Oral valganciclovir</u> (unclear mechanism)
- > Anecdotal reports of other treatments with mixed/poor results
- > Optimal duration is unclear
- > Spontaneous resolution can occur

PMID: 25446403 PMID: 33559344

## Trichodysplasia spinulosa: Treatment

"Good" efficacy	n
Oral Valganciclovir	11
Reduced Immunosuppression	5
Cidofovir 3%**	4
Oral leflunomide	2
Manual extraction	1

n=number of treatments

Adopted from: Curman et al 2021

PMID: 33559344


## Trichodysplasia spinulosa: Treatment

"No/Poor" efficacy	n
Topical retinoids	12
Topical steroids	9
Topical imiquimod	6
Topical or oral antivirals*	9
Oral retinoids	3
Topical antibiotics	3
Topical antifungals	3
Oral antibiotics	2
Oral antihistamines	2
Topical calcineurin inhibitors	2
Oral glucocorticoids	1

N=number of treatments; \*Other than cidofovir or valganciclovir

## Return to case...

- > Treated with
  - Topical Cidofovir 3% BID
  - Mupirocin 2% ointment PRN
  - Hydrocortisone 2.5% cream
  - Reduction of MPA
  - Added leflunomide
- Noted improvement with sunlight/outdoor exposure





## Trichodysplasia spinulosa: Case reports and review of literature

```
Aju Jose<sup>1</sup> | Taimur Dad<sup>1</sup> | Andrew Strand<sup>2</sup> | Julie Y. Tse<sup>3</sup> | Natalia Plotnikova<sup>4</sup> | Helen W. Boucher<sup>2</sup> | Mark J. Sarnak<sup>1</sup> | Scott J. Gilbert<sup>1</sup> | Nitender Goyal<sup>1</sup>
```

- Case report and review of literature
- 29 cases of TS in SOT
  - 10 pediatric; 19 adults
- Median age of diagnosis: 37
- Time to onset of diagnosis: 11 months
- Frequently delay in diagnosis
- Most patients treated with antivirals
  - 17/19 responded well (oral valganciclovir, topical cidofovir)

PMID: 32475005



## **Summary/Key Points**

- > Trichodysplasia Spinulosa is a rare infection caused by human polyomavirus (TSPyV)
- > Infection is common, clinical disease is rare and associated immunosuppression (SOT and hematological malignancy)
- > Consider TS in patients who present with a fleshy, spiky rash involving the mid-face
- > Treatment is not well defined but there has been reported improvement with reduction in immunosuppression, topical cidofovir 3%, and oral valganciclovir

